Abstract:The non-receptor protein tyrosine kinase c-Src regulates diverse biological processes by associating with multiple signaling and structural molecules. Overexpression of c-Src occurs in pancreatic cancer and can be predictive of poor prognosis. The aim of this study was to investigate the inhibitory effects of plasmid-based siRNAs targeting the human c-Src gene on proliferation and angiogenesis in the human pancreatic adenocarcinoma cell line Panc-1. Three siRNAs targeting the c-Src gene were transfected into the Panc-1 pancreatic adenocarcinoma cell line mediated by Lipofectamine. Transfection efficiency was assessed by flow cytometry. Real-time quantitative PCR (RQ-PCR) was employed to detect the expression of c-Src mRNA, and the most effective siRNA was chosen to be cloned into a plasmid. Two single-strand DNA templates were designed according to the most effective siRNA sequences. The short hairpin RNA (shRNA) plasm id targeting c-Src with pGPU6/green fluorescent protein (GFP)/Neo vector psiRNA-c-Src was constructed. Sequencing was performed to check whether the plasmid was constructed correctly. Panc-1 cells were transfected with psiRNA-c-Src and the negative control plasmid (psiRNA-N), respectively. Following selection with G418, the transfected monoclonal cells were chosen. GFP was evaluated by flow cytometry and fluorescence microscopy to estimate transfection efficiency. RQ-PCR and western blotting were used to detect c-Src silencing efficiency. To verify the effects of gemcitabine chemoresistance of c-Src expression, MTT assay was performed. ELISA was used to determine VEGF levels in culture supernatants. In a nude mouse model, tumor growth was studied, c-Src, VEGF expression and microvessel density in tumor tissue were measured by immunohistochemistry. The transfection efficiency of siRNA in the Panc-1 cell line was above 90%, the most effective siRNA could suppress expression of the c-Src gene with an inhibition efficiency of 86.1%. Sequencing confirmed that the c-Src siRNA plasmid was successfully constructed. MTT assay indicated that the effect of gemcitabine-induced cytotoxicity was markedly increased in the psiRNA-c-Src group (P<0.05). Meanwhile, the expression of VEGF in vitro was reduced significantly (P<0.05) in the psiRNA-c-Src group. In nude mice bearing tumors, c-Src, VEGF expression and MVD were decreased in tumors produced from psiRNA-c-Src transfected cells (P<0.05). In summary, the siRNA expression constructs targeting c-Src could specifically suppress c-Src expression, inhibit VEGF expression, inhibit cell proliferation and enhance gemcitabine chemosensitivity in vitro. C-Src gene silencingwas able to inhibit angiogenesis of tumors in vivo. These findings demonstrate that the c-Src targeting gene silencing approach has the potential to serve as a novel tool for pancreatic carcinoma treatment.

[Construction of Glucosylceramide Synthase-Specific Sirna Expression Vector and Its Efficiency in Reversal of Drug Resistance in Breast Carcinoma Cells].

Inhibition of glucosylceramide synthase expression and reversal of multidrug resistance in human breast cancer cells by shRNA

Suppression of Glucosylceramide Synthase by RNA Interference Reverses Multidrug Resistance in Human Breast Cancer Cells.

Targeting Glucosylceramide Synthase Reverses Multi-Drug Resistance in Breast Carcinoma Cells

Co-Suppression Of Mdr1 (Multidrug Resistence 1) And Gcs (Glucosylceramide Synthase) Restores Sensitivity To Mutidrug Resistance Breast Cancer Cells By Rna Interference (Rnai)

Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs

Effects of artificial microRNA targeting glucosylceramide synthase on drug sensitivity of breast cancer cells

[Reversing Multidrug Resistance in Breast Cancer Cell Line MCF-7/ADR by Small Interfering RNA].

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Sequential Therapy with Redox-Responsive Glucolipid Nanocarrier Separately Delivering Sirna and Doxorubicin to Overcome Multidrug Resistance.

A Study of the Suppressive Effect on Human Pancreatic Adenocarcinoma Cell Proliferation and Angiogenesis by Stable Plasmid-Based Sirna Silencing of C-Src Gene Expression.

Expression of Glucosylceramide Synthase in Human Doxorubicin-resistant Breast Cancer Cells and Its Significance

Reversing of Multidrug Resistance Breast Cancer by Co-Delivery of P-gp Sirna and Doxorubicin Via Folic Acid-Modified Core-Shell Nanomicelles

Construction of lentiviral vector of RNA interference and its effect on A549 and A549/DDP cells

Construction of GPR30 RNAi Vector and Characterization in Antihormone Resistant Breast Cancer Resistant Cells

In Vitro And In Vivo Inhibition Of Mrp Gene Expression And Reversal Of Multidrug Resistance By Sirna

Reversal of MDR1/P-glycoprotein-mediated Multidrug Resistance by Vector-Based RNA Interference in Vitro and in Vivo

Reversal of MDR1 Gene-Dependent Multidrug Resistance Using Short Hairpin RNA Expression Vectors

siRNAs silence expression of mdr1 gene and its role in reversing drug-resistance in K562/ADM cells

Delivery of Sirna by MRI-visible Nanovehicles to Overcome Drug Resistance in MCF-7/ADR Human Breast Cancer Cells.

Bioreducible, Arginine-Rich Polydisulfide-Based Sirna Nanocomplexes with Excellent Tumor Penetration for Efficient Gene Silencing.